Tempus AI Beats Estimates, Raises 2026 Revenue Outlook

Healthcare data and diagnostics operators should note that licensed data and testing revenue are both scaling, with data bookings above $550 million this year.

Updated on Nov. 2, 2026 in Healthcare

Tempus AI Beats Estimates, Raises 2026 Revenue Outlook

Tempus AI reported third-quarter 2026 revenue of $411.5 million, up 23% year over year and ahead of the $409 million analyst estimate, and raised its full-year revenue forecast. Shares climbed almost 10% on Monday, November 2, 2026, on the Nasdaq.

Why it matters

For operators in healthcare data and diagnostics, the results show demand for licensed clinical and genomic data growing alongside testing volume, with growth coming from both of the company's main segments. The raised forecast signals that buyers of precision-medicine data and testing services are expanding spend.

Tempus AI's Q3 2026 revenue of $411.5 million rose 23% from a year earlier and beat the $409 million analyst estimate, while Data & Applications revenue grew 33% to $108.1 million. Year-to-date data licensing bookings exceeded $550 million, and the company raised its full-year 2026 revenue forecast to $1.60–$1.61 billion.

The players

Tempus AI

A Nasdaq-listed precision-medicine company that combines clinical diagnostics with a large licensed data and research platform, serving oncology and pharmaceutical customers.

Bristol Myers Squibb

A large global pharmaceutical company that has signed data licensing agreements with Tempus AI valued at up to $137.5 million and $55 million.

Personalis

A genomics company whose acquisition by Tempus AI has cleared regulatory review.

The details

Tempus AI's growth came from both of its main segments: diagnostics revenue rose 20% to $303.5 million, and oncology unit growth accelerated to 32%. Its data licensing business reported agreements with Bristol Myers Squibb valued at up to $137.5 million and $55 million, which the company describes as part of its research platform strategy. The company also plans to expand that platform to include 100,000 whole genomes, and its acquisition of Personalis has cleared regulatory review.

Q3 2026: Tempus AI reported third-quarter revenue and adjusted earnings.
Monday, November 2, 2026: Shares climbed almost 10% after the earnings report.
Full-year 2026: The company raised its revenue forecast to $1.60–$1.61 billion.

Market Landscape

Tempus AI's licensing agreements with Bristol Myers Squibb, valued at up to $137.5 million and $55 million, illustrate pharmaceutical companies paying for clinical and genomic datasets to support drug development. The company's data licensing bookings exceeding $550 million year to date show this revenue line expanding alongside its diagnostics business.

Operators in healthcare data, diagnostics, and pharmaceutical services should watch how buyers allocate spend between testing volume and licensed data, since both grew at double-digit rates this quarter. Procurement and business-development teams evaluating data partnerships may want to track licensing terms of this kind as a reference point.

The takeaway

The main operating signal is that licensed data and diagnostics are both scaling, which suggests recurring data revenue can grow as fast as testing volume. Operators should track whether the company's next-quarter data bookings continue to outpace diagnostics growth as the 2026 forecast is delivered.